Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

NetraMark Holdings Inc C.AIAI

Alternate Symbol(s):  AINMF

NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.


CSE:AIAI - Post by User

Post by waves1on Feb 11, 2022 2:36pm
138 Views
Post# 34421361

$MEND & Cyclica partner for novel drug development

$MEND & Cyclica partner for novel drug development
Exciting news for Nurosene Health Inc. ($MEND.c $MNNDF) yesterday as they announced a partnership with Cyclica to accelerate drug discovery and novel drug development targeting neurodegenerative diseases, a market valued at almost USD$40B.
 
Nurosene will lead in the discovery phase of the research process by identifying specific drug targets, leveraging NetraHealthAtlas (NHA), one of Nurosene's core proprietary AI tools, to accelerate identification while significantly reducing the cost and time associated with bringing a drug to the market.
 
NHA creates highly accurate hypotheses about invisible causal factors from patient sub-populations and then recommends ways to target diseases by exploring the necessary biochemistry involved. 
 
Cyclica is a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline. Using their AI-augmented drug discovery platform, Cyclica will focus on discovering novel drug candidates for drug targes discovered by NHA
 
I'm looking forward to the results of this partnership as it has the potential to make revolutionary drug discoveries for neurodegenerative diseases.
 
https://www.biospace.com/article/releases/nurosene-and-amp-cyclica-partner-to-develop-novel-drugs-for-neurodegenerative-diseases/ 
<< Previous
Bullboard Posts
Next >>